Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Patient Preference 1Leiomyoma 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1Agnosia 1

Interventions

Cyclophosphamide 909Carboplatin 786Paclitaxel 741pembrolizumab 741Bevacizumab 715Cisplatin 707Gemcitabine 621Docetaxel 583Rituximab 558Radiotherapy 546Dexamethasone 510Nivolumab 488Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 357Pemetrexed 336Oxaliplatin 335Cytarabine 334Lenalidomide 327Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 315Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 275

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Injections, Subcutaneous × Clear all
NCT05415215 2026-02-10

ProHer

Hoffmann-La Roche

Phase 3 Completed
346 enrolled 20 charts
Breast

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT02270255 2019-08-14

Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Completed
44 enrolled 8 charts

Agnosia, Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡